Viking Therapeutics, Inc. rebounded 50% after a sharp drop, returning to pre-selloff levels despite no major internal catalysts. VKTX's recovery is likely driven by broader developments in the GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results